Mutational Analysis of Glycogen Synthase Kinase 3β Protein Kinase Together with Kinome-Wide Binding and Stability Studies Suggests Context-Dependent Recognition of Kinases by the Chaperone Heat Shock Protein 90

ABSTRACT The heat shock protein 90 (HSP90) and cell division cycle 37 (CDC37) chaperones are key regulators of protein kinase folding and maturation. Recent evidence suggests that thermodynamic properties of kinases, rather than primary sequences, are recognized by the chaperones. In concordance, we observed a striking difference in HSP90 binding between wild-type (WT) and kinase-dead (KD) glycogen synthase kinase 3β (GSK3β) forms. Using model cell lines stably expressing these two GSK3β forms, we observed no interaction between WT GSK3β and HSP90, in stark contrast to KD GSK3β forming a stable complex with HSP90 at a 1:1 ratio. In a survey of 91 ectopically expressed kinases in DLD-1 cells, we compared two parameters to measure HSP90 dependency: static binding and kinase stability following HSP90 inhibition. We observed no correlation between HSP90 binding and reduced stability of a kinase after pharmacological inhibition of HSP90. We expanded our stability study to >50 endogenous kinases across four cell lines and demonstrated that HSP90 dependency is context dependent. These observations suggest that HSP90 binds to its kinase client in a particular conformation that we hypothesize to be associated with the nucleotide-processing cycle. Lastly, we performed proteomics profiling of kinases and phosphopeptides in DLD-1 cells to globally define the impact of HSP90 inhibition on the kinome.

[1]  T. Pawson,et al.  Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy , 2015, Science Signaling.

[2]  A. Gingras,et al.  Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor , 2015, Proceedings of the National Academy of Sciences.

[3]  S. Rüdiger,et al.  Hsp90 interaction with clients. , 2015, Trends in biochemical sciences.

[4]  M. Sherman,et al.  Hsp70 in cancer: back to the future , 2014, Oncogene.

[5]  Bonnie Berger,et al.  A Quantitative Chaperone Interaction Network Reveals the Architecture of Cellular Protein Homeostasis Pathways , 2014, Cell.

[6]  Tony Pawson,et al.  CoreFlow: a computational platform for integration, analysis and modeling of complex biological data. , 2014, Journal of proteomics.

[7]  D. Proia,et al.  Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. , 2014, Cancer research.

[8]  L. Neckers,et al.  Stressing the Development of Small Molecules Targeting HSP90 , 2013, Clinical Cancer Research.

[9]  L. Paz-Ares,et al.  Inhibition of HSP90 molecular chaperones: moving into the clinic. , 2013, The Lancet. Oncology.

[10]  Paul Workman,et al.  ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. , 2013, Nature chemical biology.

[11]  D. Agard,et al.  Uncovering a region of heat shock protein 90 important for client binding in E. coli and chaperone function in yeast. , 2013, Molecular cell.

[12]  Susan Lindquist,et al.  Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition , 2012, Cell.

[13]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[14]  Bernhard Kuster,et al.  Systematic Identification of the HSP90 Regulated Proteome , 2012, Molecular & Cellular Proteomics.

[15]  G. Drewes,et al.  Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics , 2012, BMC Cancer.

[16]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[17]  Pablo C. Echeverría,et al.  An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.

[18]  D. Bolon,et al.  Hsp90 and client protein maturation. , 2011, Methods in molecular biology.

[19]  L. Regan,et al.  Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP. , 2010, Biochemistry.

[20]  G. Giaccone,et al.  Update on Hsp90 inhibitors in clinical trial. , 2009, Current topics in medicinal chemistry.

[21]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[22]  D. Sternberg,et al.  Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context. , 2007, Experimental cell research.

[23]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[24]  A. K. Mandal,et al.  Molecular chaperones and protein kinase quality control. , 2007, Trends in cell biology.

[25]  P. Lochhead,et al.  A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. , 2006, Molecular cell.

[26]  L. Neckers Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. , 2006, Current topics in medicinal chemistry.

[27]  S. Pietrokovski,et al.  Hsp90 Recognizes a Common Surface on Client Kinases* , 2006, Journal of Biological Chemistry.

[28]  Laurence H Pearl,et al.  Hsp90 and Cdc37 -- a chaperone cancer conspiracy. , 2005, Current opinion in genetics & development.

[29]  Zhexin Xiang,et al.  Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex , 2005, Nature Structural &Molecular Biology.

[30]  T. Pawson,et al.  Proteomic, Functional, and Domain-Based Analysis of In Vivo 14-3-3 Binding Proteins Involved in Cytoskeletal Regulation and Cellular Organization , 2004, Current Biology.

[31]  R. Matts,et al.  Phosphorylation of Serine 13 Is Required for the Proper Function of the Hsp90 Co-chaperone, Cdc37* , 2003, Journal of Biological Chemistry.

[32]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[33]  Laurence H. Pearl,et al.  Crystal Structure of Glycogen Synthase Kinase 3β Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition , 2001, Cell.

[34]  P. Cohen,et al.  A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. , 2001, Molecular Cell.

[35]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[36]  Y. Yarden,et al.  Sensitivity of Mature ErbB2 to Geldanamycin Is Conferred by Its Kinase Domain and Is Mediated by the Chaperone Protein Hsp90* , 2001, The Journal of Biological Chemistry.

[37]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Benjamin,et al.  Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  J. Woodgett,et al.  Modulation of the glycogen synthase kinase‐3 family by tyrosine phosphorylation. , 1993, The EMBO journal.

[40]  H. Wiley,et al.  Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor. , 1990, The Journal of biological chemistry.